

RESEARCH

Open Access



Prevalence of depression and association with all-cause and cardiovascular mortality among individuals with type 2 diabetes: a cohort study based on NHANES 2005–2018 data

Zhen Feng^{1,2}, Wai Kei Tong¹, Xinyue Zhang¹ and Zhijia Tang^{1*}

Abstract

Background Individuals with diabetes have increased risk of depression, but there are limited nationally representative studies on this topic. We aimed to investigate the prevalence and predictors of depression, as well as its impact on all-cause and cardiovascular mortality in adults with type 2 diabetes (T2DM) using a prospective cohort study and a representative sample of the U.S. population.

Methods We analyzed National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2018 and linked it with the most recent publicly available National Death Index (NDI) data. Individuals aged 20 years or old who had depression measurements were included. Depression was defined as a Patient Health Questionnaire (PHQ-9) score ≥ 10 , and categorized into moderate (10–14 points) and moderately severe to severe (≥ 15 points). Cox proportional hazard models were used to estimate the association between depression and mortality.

Results Among 5695 participants with T2DM, 11.6% had depression. Depression was associated with female gender, younger age, overweight, lower education, being unmarried, smoking, and a history of coronary heart disease and stroke. During a mean follow-up period of 78.2 months, 1161 all-cause deaths occurred. Total depression and moderately severe to severe depression significantly increased all-cause mortality (adjusted hazard ratio [aHR] 1.36, 95% CI [1.09–1.70]; 1.67 [1.19–2.34]) and non-cardiovascular mortality (aHR 1.36, 95% CI [1.04–1.78]; 1.78, 95% CI [1.20–2.64]), but not cardiovascular mortality. Subgroup analysis showed a significant association between total depression and all-cause mortality in males (aHR 1.46, 95% CI [1.08–1.98]) and those aged 60 years or older (aHR 1.35, 95% CI [1.02–1.78]). Any severity of depression was not significantly associated with cardiovascular mortality in age- or gender- stratified subgroups.

Conclusions In a nationally representative sample of U.S. adults with T2DM, approximately 10% experienced depression. Depression did not significantly associate with cardiovascular mortality. However, comorbid depression in

*Correspondence:
Zhijia Tang
zjtang@fudan.edu.cn

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

T2DM patients increased the risk of all-cause and non-cardiovascular mortality. The impact of depression on mortality varied across subgroups. Therefore, healthcare providers should consider incorporating depression screening and management into routine care, especially for subgroups with specific risk factors, due to the increased risk of all-cause mortality in T2DM patients with depression.

Keywords Depression, Diabetes, Mortality, Prevalence, NHANES, Risk factor

Background

Depression, a prevalent and severe mental illness characterized by sadness, loss of interest or pleasure, low self-worth, loss of sleep or appetite, tiredness, and difficulty concentrating [1], affects more than 300 million people of all ages globally [2], and is associated with significant social and economic consequences, including lost productivity and expanded healthcare costs [3, 4]. Between 1990 and 2019, depression was one of the primary factors impacting disability-adjusted life-years (DALYs) and was the leading cause of death worldwide [5].

Depression is closely associated with chronic diseases, such as type 2 diabetes (T2DM), which has been linked to a higher prevalence of depressive symptoms [6–11]. For instance, the prevalence of clinically relevant depression (defined as a Patient Health Questionnaire [PHQ-9] score ≥ 10) and clinically significant depression (PHQ-9 score ≥ 15) in U.S. adults with T2DM was 10.6% and 4.2%, respectively, between 2005 and 2012, with no significant changes over time [12]. Furthermore, a bidirectional relationship has been established between T2DM and depression. The risk of incident T2DM was higher in individuals with depressive symptoms. Diabetes, in turn, increases the risk of incident depression and can lead to more severe symptoms [13]. Several factors, such as female gender, low birth weight, adverse childhood events, lifestyle, obesity, cognitive dysfunction, and migration, have been identified to influence the development of comorbid diabetes and depression through multiple mechanisms [14–16].

Individuals with comorbid depression and T2DM have a higher risk of all-cause and cardiac-related death compared to those without depression [17–20]. Multiple studies have demonstrated the negative impact of concomitant T2DM and depression on all-cause mortality [21–24], with remarkably higher risk reported in specific subgroups, such as individuals aged over 75 years (hazard ratio [HR] 6.04) [22], postmenopausal women (HR 5.02) [25], Mexican Americans (odds ratio [OR] 4.04) [26], and individuals with heart failure (HR 3.71) [27]. Other predictive factors include insulin use (HR 2.37), lower limb amputation (HR 1.99), and male gender (HR 1.90) [22].

The mechanisms underlying the increased risk of death in individuals with comorbid depression and diabetes are not fully understood and may be multifactorial. Both physiological and behavioral factors may contribute to it. Hypothalamic-pituitary-adrenal (HPA) axis, sympathetic

nervous system (SNS), pro-inflammatory cytokines, and platelet dysfunction, have been suggested to induce CVD and mortality in individuals with comorbid depression [21, 25, 28, 29]. In addition, chronically ill patients with comorbid depression and diabetes tend to have unhealthy behaviors, such as unhealthy diet and lifestyle, low physical activity, smoking [24], as well as poor self-management [30], and non-adherence [31], all of which can worsen short- and long-term clinical outcomes.

However, due to limitations such as small sample size, limited age range, diverse screening tools, and short follow-up time, it is difficult to identify which factors play a major role in increasing this risk. Nor is there established evidence for predicting the comorbid occurrence of diabetes and depression in large populations. One meta-analysis showed that comorbid depression significantly increased the risk of death in people with diabetes; however, the included studies were either from the community or from hospitals or other primary care settings, and no national samples were surveyed [32]. Also, it remains unclear whether the findings are consistent across subpopulations. Considering the adverse health outcomes of these two diseases, there is an urgent need to identify vulnerable subgroups and provide personalized treatment. Moreover, identifying factors linking comorbid depressive symptoms and subsequent death can be an important strategy for diabetes management. In this study, we took advantage of data from the National Health and Nutrition Examination Survey (NHANES), a larger nationwide sample size, to obtain comprehensive results. The objective of this study was to investigate the impact of depression on all-cause and cardiovascular mortality in adults with T2DM, as well as the prevalence and predictors of depression in this population.

Methods

Data source and study population

This study used data from the NHANES conducted between 2005 and 2018. The NHANES is a cross-sectional survey that utilizes a complex, multistage, stratified, clustered probability design [33]. It is a nationally representative sample of the civilian non-institutionalized U.S. population.

Initially, the study included 39749 adults over the age of 20. Of these, 6766 were diagnosed with diabetes. We excluded pregnant women ($n=12$), individuals with probable type 1 diabetes ($n=216$), those with no measures of

depression ($n=835$), and those lost to follow-up ($n=8$). Ultimately, 5695 eligible subjects were included in this analysis.

Assessment of T2DM

In this study, we defined T2DM as either a self-reported diagnosis by a physician, plasma HbA1c $\geq 6.5\%$, or fasting plasma glucose ≥ 7.0 mmol/L [34]. We excluded subjects who had possible type 1 diabetes, were diagnosed with diabetes before the age of 30, started insulin within two years of diagnosis, or were currently using insulin [35, 36]. Physician-diagnosed diabetes records were obtained during household interviews.

Measurement of depression

The PHQ-9 questionnaire has been used to screen depression in NHANES since 2005. It is a reliable and internally consistent assessment tool recommended for measuring depression severity [36, 37]. The PHQ-9 total score ranges from 0 to 27, with a score of ≥ 10 indicating depression. We further subdivided the PHQ-9 scores into three categories: 10–14 points (moderate), 15–19 points (moderately severe), and ≥ 20 points (severe) [17]. Due to the relatively low prevalence of severe depression, we combined the “moderately severe” and “severe” categories into “moderately severe to severe depression” [17].

Ascertainment of mortality data

We used the Public-use Linked Mortality Files (LMF) from the National Death Index (NDI) as of December 31, 2019, to ascertain mortality data [5]. Causes of death were coded according to the International Classification of Diseases 10th Revision (ICD-10). The endpoints included mortality from all causes, cardiovascular and non-cardiovascular mortality. The deaths related to cardiovascular disease were classified as those coded I00–I09, I11, I13, and I20–I51, while non-cardiovascular deaths encompassed all other causes.

Covariates

We included several variables as covariates in our analysis, including age, gender, body mass index (BMI), race/ethnicity, education level, marital status, smoking status, and medical history of hypertension, coronary heart disease (CHD), and stroke. Marital status was categorized as cohabitated (including married and living with a partner) and solitary (including widowed, divorced, separated, and never married). Smoking status was categorized as never smokers and smokers (including current smoking and smoking history). Hypertension was defined as systolic blood pressure (SBP) ≥ 130 mmHg, diastolic blood pressure (DBP) ≥ 80 mmHg, self-reported hypertension, or use of antihypertensive medications, with SBP and DBP

calculated as the average of all available blood pressure measurements. Both CHD and stroke were self-reported.

Statistical analysis

For the descriptive statistics, we used mean (standard error, SE) for continuous variables and the number (weighted percentage, %) for categorical variables. We described the baseline depressive status using the PHQ-9 score and compared differences between groups using the Chi-square test. To identify risk factors for depression in patients with T2DM, logistic regression was conducted to calculate odds ratios (ORs). Adjusted ORs were obtained through multivariate regression analyses using the selection methods to account for potential confounding variables. Confounding was assessed by entering potential cofounders into a logistic regression model one at a time. The selection of relevant covariates was based on their relationship with the outcomes of interest, such as baseline characteristics and disease history. Follow-up time was calculated using person-months from the date of interview to the date of death or the end of the follow-up period (December 31, 2019), whichever came first. We calculated the incidence rates of all-cause and cardiovascular mortality by dividing the number of events by the follow-up person-years. Multivariate Cox proportional hazards models were used to estimate HRs with 95% confidence intervals (CIs) of all covariates.

All data were weighted to ensure an appropriate estimate and representative of the total civilian non-institutionalized U.S. population. All statistical analyses were performed using the Survey package in R statistical software (version R 4.2.1 for macOS). A two-sided $p < 0.05$ was considered to be statistically significant.

Results

Baseline characteristics of study population

Table 1 showed the baseline characteristics of participants based on depression status from NHANES. We included 5695 participants with T2DM, of whom 722 (weighted percentage 11.6%) had depression. The weighted mean age was 57.4 ± 0.7 years in the depression group and 60.3 ± 0.3 years in the non-depression group. Depressed individuals were more likely to be younger, female, overweight, less educated, solitary, current smoker, and have a history of stroke than those without depression (all p values < 0.05).

Prevalence and risk factors of depression in adults with T2DM

The prevalence of depression in adults with T2DM remained stable between 2005 and 2018, both from an overall and subgroup perspective ($p > 0.05$ for all linear trends, supplementary Table S1). Table 2 suggested that the risk of depression was significantly lower in

Table 1 Baseline characteristics of study population, NHANES 2005–2018

Characteristics	Total (n = 5695)	Non-depression (n = 4973)	Depression (n = 722)	P value
Age, years	59.9 ± 0.3	60.3 ± 0.3	57.4 ± 0.7	< 0.001
< 60	2156 (46.3)	1826 (45.2)	330 (54.1)	0.004
≥ 60	3539 (53.7)	3147 (54.8)	392 (45.9)	
Gender				
Male	2994 (52.2)	2716 (54.4)	278 (35.3)	< 0.001
Female	2701 (47.8)	2257 (45.6)	444 (64.7)	
BMI, kg/m ²				
< 25	717 (10.7)	647 (11.0)	70 (7.7)	< 0.001
25–30	1580 (25.3)	1446 (26.8)	134 (14.1)	
≥ 30	3295 (64.0)	2795 (62.2)	500 (78.2)	
Race/ethnicity				
Non-Hispanic white	1978 (61.3)	1717 (61.5)	261 (59.2)	0.718
Non-Hispanic black	1522 (15.2)	1351 (15.1)	171 (15.9)	
Mexican American	1047 (9.8)	909 (9.7)	138 (10.4)	
Other races	1148 (13.8)	996 (13.7)	152 (14.5)	
Education level				
Below high school	1942 (23.4)	1608 (21.9)	334 (35.0)	< 0.001
High school/Some college	2864 (56.6)	2528 (56.7)	336 (56.3)	
College graduate or above	881 (20.0)	831 (21.4)	50 (8.7)	
Marital status				
Cohabitated	3378 (63.8)	3040 (65.4)	338 (51.1)	< 0.001
Solitary	2311 (36.2)	1928 (34.6)	383 (48.9)	
Smoking status				
Never smoker	2817 (48.7)	2523 (49.8)	294 (39.6)	< 0.001
Past smoker	1949 (35.4)	1716 (35.9)	233 (31.7)	
Current smoker	925 (15.9)	730 (14.2)	195 (28.7)	
Drinking status				
Non-drinker	2894 (98.6)	2577 (98.7)	317 (97.2)	0.155
Drinker	54 (1.4)	45 (1.3)	9 (2.8)	
Hypertension	4589 (80.3)	944 (80.1)	600 (82.0)	0.356
Coronary heart disease	572 (11.2)	481 (10.8)	91 (14.5)	0.092
Stroke	497 (8.1)	401 (7.6)	96 (12.4)	< 0.001

Continuous variables were presented as mean ± SE. Categorical variables were presented as number and weighted percentage. Abbreviations: BMI body mass index

people aged 60 years and older compared to those under 60 (adjusted OR [aOR] 0.77, 95% CI [0.59–1.00]). High school and college graduate or above education also reduced the probability of depression compared to those with a degree below high school (aOR 0.62, 95% CI [0.48–0.79]; aOR 0.33, 95% CI [0.21–0.51]). In contrast, depression was more prevalent among females (aOR 2.02, 95% CI [1.59–2.56]), individuals with BMI ≥ 30 kg/m² (aOR 1.92, 95% CI [1.33–2.76]), solitary individuals (aOR 1.47, 95% CI [1.13–1.90]), current smokers (aOR 2.41, 95% CI [1.86–3.11]), and those with a history of CHD (aOR 1.69, 95% CI [1.10–2.58]) and stroke (aOR 1.65, 95% CI [1.20–2.29]).

Association of depression with all-cause and cardiovascular mortality in adults with T2DM

The study found that during an average follow-up period of 78.2 months (depression group: 75.3 months; non-depression group: 78.5 months), there were 1161 deaths,

including 323 cardiovascular deaths. The incidence rates of all-cause and CVD mortality among participants with depression were higher than those without depression (Table 3).

After adjusting for covariates, both total depression and moderately severe to severe depression demonstrated a significant association with an increased risk of all-cause death when compared to individuals without depression (adjusted HR [aHR] 1.36, 95% CI [1.09–1.70] and 1.67, 95% CI [1.19–2.34], respectively). Additionally, total depression and moderately severe to severe depression were found to increase the risk of non-cardiovascular mortality among adults with T2DM (aHR 1.36, 95% CI [1.04–1.78] and 1.78, 95% CI [1.20–2.64], respectively). However, no significant association was found between any severity of depression and cardiovascular mortality (Table 3). These findings suggest that depression is a risk factor for all-cause mortality in adults with T2DM but may not be associated with cardiovascular mortality.

Table 2 Odds ratios for depression in participants with different characteristics

Characteristics	Odds ratio (95% CI)	
	Unadjusted	Adjusted
Age, years		
< 60	1.00 (reference)	1.00 (reference)
≥ 60	0.70 (0.55–0.89)	0.77 (0.59–1.00)
Gender		
Male	1.00 (reference)	1.00 (reference)
Female	2.18 (1.75–2.72)	2.02 (1.59–2.56)
BMI, kg/m ²		
< 25	1.00 (reference)	1.00 (reference)
25–30	0.76 (0.52–1.13)	0.86 (0.57–1.30)
≥ 30	1.81 (1.29–2.55)	1.92 (1.33–2.76)
Race		
Non-Hispanic white	1.00 (reference)	1.00 (reference)
Non-Hispanic black	1.10 (0.86–1.41)	0.78 (0.60–1.02)
Mexican American	1.12 (0.86–1.45)	0.84 (0.63–1.13)
Other	1.10 (0.80–1.52)	1.09 (0.78–1.51)
Education level		
Below high school	1.00 (reference)	1.00 (reference)
High school/Some college	0.62 (0.49–0.79)	0.62 (0.48–0.79)
College graduate or above	0.25 (0.17–0.39)	0.33 (0.21–0.51)
Marital status		
Cohabitated	1.00 (reference)	1.00 (reference)
Solitary	1.81 (1.43–2.30)	1.47 (1.13–1.90)
Smoking status		
Never smoker	1.00 (reference)	1.00 (reference)
Past smoker	1.11 (0.87–1.42)	1.25 (0.96–1.62)
Current smoker	2.54 (1.92–3.34)	2.41 (1.86–3.11)
Drinking status		
Non-drinker	1.00 (reference)	1.00 (reference)
Drinker	2.21 (0.72–6.80)	1.80 (0.59–5.50)
Hypertension		
No	1.00 (reference)	1.00 (reference)
Yes	1.13 (0.87–1.45)	1.09 (0.83–1.41)
Coronary heart disease		
No	1.00 (reference)	1.00 (reference)
Yes	1.40 (0.94–2.07)	1.69 (1.10–2.58)
Stroke		
No	1.00 (reference)	1.00 (reference)
Yes	1.73 (1.28–2.35)	1.65 (1.20–2.29)

Multivariate logistic regression adjusted for age, gender, BMI, education level, marital and smoking status, and history of stroke (categorical). Numbers in bold indicated significant findings. Abbreviations: BMI body mass index; CI confidence interval

Hazard ratios for all-cause and cardiovascular mortality in subgroups

We conducted a subgroup analysis to address the age- and gender-specific considerations regarding the impact of depression on mortality risk in patients with T2DM (Table 4). The association between total depression and all-cause mortality was only significant in individuals aged 60 years or older (aHR 1.35, 95% CI [1.02–1.78]) and males (aHR 1.46, 95% CI [1.08–1.98]). Furthermore,

moderately severe to severe depression significantly increased the risk of all-cause death in both subgroups compared to those without depressive symptoms (aHR 1.69, 95% CI [1.10–2.58]; aHR 1.75, 95% CI [1.06–2.90]). No remarkable association with cardiovascular mortality was observed in any age or gender subgroups, consistent with the overall results. When considering non-cardiovascular mortality, the association between total depression and non-cardiovascular mortality was significant only in people aged 60 years or older (aHR 1.40, 95% CI [1.00–1.96]). Additionally, moderately severe to severe depression significantly increased the risk of non-cardiovascular death in people aged 60 years or older (aHR 1.87, 95% CI [1.15–3.05]) and males (aHR 1.86, 95% CI [1.02–3.42]).

Discussion

This is a large-scale, prospective, long-term follow-up, nationally representative cohort study. We estimated the prevalence of depression and its predictors, as well as the effects of depression on all-cause, cardiovascular mortality and non-cardiovascular mortality in patients with T2DM, at the overall and subgroup levels, which are rarely reported.

Prevalence of depression and its predictors in individuals with T2DM

In this study, we estimated the overall prevalence of depression, as measured by a PHQ-9 score ≥ 10, was 11.6% in T2DM patients over 20 years of age. The National Survey on Drug Use and Health (NSDUH) found that the prevalence of depression was 7.1% in all U.S. adults. Consistently, it was thought that comorbid T2DM increased the risk of depression and may lead to a more severe course of depression [16]. This is consistent with previous research but with stability over a longer period [12, 38]. However, caution must be exercised in generalizing the findings to other countries due to possible variations in participant samples, study sites, and methods of assessing depression [39, 40].

Therefore, it is important to explore the prevalence of depression and its predictors across different populations and setting to better understand the burden of this comorbidity. The 2015–2018 NHANES data showed an increased prevalence of depression in almost all subgroups of people with T2DM [11, 18]. In this study, we observed that sociodemographic variables such as younger age, female gender, lower educational level, being overweight or unmarried, smoking, and a history of chronic medical conditions were major predictors of depression among patients with T2DM. These findings highlight the need for targeted interventions to address the unique risk factors.

Table 3 Hazard ratios for all-cause, cardiovascular and non-cardiovascular mortality in participants with depression, stratified by severity

Depression status	Cases/person-years	Incidence per 1000 person-years	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
<i>All-cause mortality</i>				
Non-depression	992/33042	27.05	1.00 (reference)	1.00 (reference)
Total depression	169/4610	33.39	1.24 (1.02–1.53)	1.36 (1.09–1.70)
Moderate	100/2690	31.01	1.15 (0.91–1.46)	1.20 (0.95–1.52)
Moderately severe to severe	69/1921	37.53	1.40 (0.99–1.99)	1.67 (1.19–2.34)
<i>Cardiovascular mortality</i>				
Non-depression	274/33042	7.40	1.00 (reference)	1.00 (reference)
Total depression	49/4610	9.13	1.24 (0.83–1.85)	1.34 (0.90–2.02)
Moderate	28/2690	8.92	1.20 (0.76–1.92)	1.34 (0.84–2.12)
Moderately severe to severe	21/1921	9.49	1.30 (0.71–2.36)	1.36 (0.70–2.66)
<i>Non-CVD mortality</i>				
Non-depression	718/33042	19.64	1.00 (reference)	1.00 (reference)
Total depression	120/4610	24.26	1.25 (0.99–1.57)	1.36 (1.04–1.78)
Moderate	72/2690	22.08	1.14 (0.86–1.49)	1.15 (0.86–1.55)
Moderately severe to severe	48/1921	28.04	1.44 (0.97–2.14)	1.78 (1.20–2.64)

Adjustment for age, gender, body mass index, education level, race, marital and smoking status, and history of hypertension, coronary heart disease, and stroke. Incidence and correlation were weighted. Numbers in bold indicated significant findings. Abbreviations: HR hazard ratio; CI confidence interval; CVD cardiovascular disease

Table 4 Adjusted hazard ratios for all-cause, cardiovascular and non-cardiovascular mortality in participants with different severity of depression, stratified by age and gender

Characteristics	Adjusted HR (95% CI)		
	Total depression	Moderate depression	Moderately severe to severe depression
<i>All-cause mortality</i>			
Age, years			
< 60	1.31 (0.83–2.06)	1.17 (0.63–2.17)	1.53 (0.87–2.70)
≥ 60	1.35 (1.02–1.78)	1.19 (0.88–1.61)	1.69 (1.10–2.58)
Gender			
Male	1.46 (1.08–1.98)	1.34 (0.93–1.93)	1.75 (1.06–2.90)
Female	1.32 (0.98–1.78)	1.15 (0.84–1.56)	1.64 (0.96–2.78)
<i>Cardiovascular mortality</i>			
Age, years			
< 60	1.65 (0.72–3.78)	1.63 (0.54–4.95)	1.70 (0.68–4.23)
≥ 60	1.21 (0.74–1.99)	1.20 (0.68–2.11)	1.23 (0.51–2.95)
Gender			
Male	1.54 (0.95–2.50)	1.59 (0.94–2.70)	1.43 (0.55–3.72)
Female	1.25 (0.73–2.15)	1.19 (0.66–2.15)	1.37 (0.55–3.41)
<i>Non-CVD mortality</i>			
Age, years			
< 60	1.23 (0.74–2.05)	1.07 (0.53–2.14)	1.49 (0.77–2.89)
≥ 60	1.40 (1.00–1.96)	1.19 (0.82–1.72)	1.87 (1.15–3.05)
Gender			
Male	1.43 (0.95–2.15)	1.25 (0.75–2.06)	1.86 (1.02–3.42)
Female	1.35 (0.95–1.91)	1.13 (0.79–1.61)	1.74 (0.94–3.20)

Reference: non-depression group. Adjustment for age, gender, body mass index, education level, race, marital and smoking status, and history of hypertension, coronary heart disease, and stroke. Abbreviations: HR hazard ratio; CI confidence interval; CVD cardiovascular disease. Numbers in bold indicated significant findings

Younger people with T2DM tend to be more vulnerable to depression due to their increased susceptibility to negative life events, such as being diagnosed with a chronic disease, which may lead to worse moods, more distress, and more depression than older adults [38, 41]. Additionally, they may lack the coping skills and experience to effectively manage these situations and help reduce the perception of harmful consequences [7]. These findings suggest the importance of targeting depression screening and intervention efforts toward younger T2DM patients, in order to mitigate the potential negative impact of depression on their overall health outcomes.

Women in this study were twice as likely as men to suffer from depression (15.6% vs. 7.8%; aOR 2.02), consistent with prior evidence [38, 42, 43]. Higher screening rates and women's inherent predisposition to depression may partly explain this gender difference [44]. We also observed that depression was more prevalent among individuals with lower levels of education, which is consistent with previous research indicating the protective effect of higher education against anxiety and depression resulting from improvements in financial hardship, physical health, and occupational restrictions [45]. Regarding marital and smoking status, a meta-analysis suggests that single or unmarried people with depression have worse prognoses [46]. The association between smoking and mental illness has long been suspected, but causality and underlying mechanisms remain to be studied [47]. Both were consistent with our results.

In addition, many studies have shown that depression frequently coexists with chronic diseases [3, 48–52]. Our findings suggested an increased risk of depression in diabetic patients with CHD (aOR=1.69) and stroke (aOR=1.65). These findings emphasize the importance of identifying and treating depression in patients with T2DM, especially those with comorbidities.

Impact and risk factors on mortality of comorbid T2DM and depression

In this study, we observed that patients with T2DM and depression, especially moderately severe to severe depression, had higher all-cause and non-cardiovascular mortality than those without depression, while depression of any severity had no significant effect on cardiovascular mortality. Our results were consistent with most previous studies on all-cause mortality but differed on cardiovascular mortality [21, 53–55]. Differences in participant characteristics, diagnostic criteria, duration of follow-up, treatment regimens, and potential confounders in the final model may be underlying the reason.

Regarding the risk factors for mortality, our subgroup analysis revealed that age and gender played different roles. The association between total depression and all-cause mortality was more pronounced among individuals

aged 60 years or older, while it was not statistically significant in younger subjects. The reason for this disparity is unknown, and further studies are needed. Moreover, although women were found to be at greater risk of developing depression, subgroup analysis demonstrated that depression had a greater impact on all-cause mortality in men. Previous studies have consistently suggested that poor psychological status has a more profound effect on mortality in men [19, 56], possibly because men are less likely to seek help for mental health issues than women [57–59]. Another pathophysiological explanation for this is that men are more susceptible to lipid oxidative damage caused by depression, which could be a key event in the etiology of atherosclerosis and CVD [19, 60].

As the severity of depression escalates, its impact on mortality becomes more prominent, both overall and within subgroups. To our knowledge, few studies have explored the effect of depression severity on mortality, making our study particularly noteworthy. However, due to the small sample size of some subgroups, our study may still be underpowered to detect statistically significant differences. Further studies with larger samples and longer follow-ups are warranted to confirm these findings.

As NHANES did not include prescribing details, it was unclear whether antidepressants helped reduce mortality in our study. Considering the close association of depression with poor self-management, interventions targeting self-care behaviors may be beneficial. Clinicians should also pay special attention to suicidal attempts, which are a common cause of death, particularly among older adults with depression [61].

This study had several limitations that should be taken into consideration. First, we relied on self-reported demographic data and the PHQ-9 questionnaire, which was not validated and may have resulted in the misclassification of participants. Additionally, due to a lack of information, there may be unmeasured confounding factors that we were unable to adjust for, such as the family history of depression and diabetes, glycemic control, medication use, disease duration, behavioral changes, and the presence of other comorbidities. Lastly, the time-frame of our study did not include the COVID-19 pandemic, which has had a substantial impact on people's psychological well-being.

Conclusions

In conclusion, we reported the prevalence of depression in T2DM patients using the NHANES 2005–2018 dataset and identified several predictors of depression. We found that the presence of comorbid depression in T2DM patients is associated with an increased mortality risk relative to those without depression. Specifically, depression was associated with more than 30% increased

risk of all-cause and non-cardiovascular death, while no significant association was observed with cardiovascular mortality. Furthermore, the impact of depression on mortality varied depending on gender and age, with older patients and males with T2DM experiencing a high risk of all-cause and non-cardiovascular death. These findings emphasize the importance of mental health awareness and management for patients with T2DM, particularly among subgroups with specific risk factors.

Abbreviations

BMI	body mass index
CHD	coronary heart disease
CI	confidence interval
DALYs	disability-adjusted life-years
DBP	diastolic blood pressure
HPA	Hypothalamic-pituitary-adrenal
HR	hazard ratio
ICD-10	International Classification of Diseases 10th Revision
LMF	Linked Mortality Files
NDI	National Death Index
NHANES	National Health and Nutrition Examination Survey
NSDUH	National Survey on Drug Use and Health
PHQ-9	Patient Health Questionnaire
SBP	systolic blood pressure
SE	standard error
SNS	sympathetic nervous system

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12888-023-04999-z>.

Supplementary Material 1

Acknowledgements

We acknowledge all the participants in this study.

Authors' contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by W.T., X.Z and Z.F. The manuscript was written by Z.F., with input from all authors. Z.T. reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the start-up grant for Zhijia Tang by Fudan University (No. J1F301025Y).

Data Availability

The datasets generated and/or analyzed during the current study are publicly available from CDC National Center for Health Statistics (<https://www.cdc.gov/nchs/nhanes/index.htm>).

Declarations

Ethics approval and consent to participate

The study was exempt from Institutional Review Board review as it used de-identified, publicly available data.

Consent for publication

Not applicable.

Competing interests

Author details

¹Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai 201203, China

²Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou 221002, China

Received: 9 May 2023 / Accepted: 4 July 2023

Published online: 10 July 2023

References

- Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. *Nat Neurosci*. 2007;10(9):1116–24. <https://doi.org/10.1038/nn1944>.
- Trivedi MH. Major depressive disorder in primary care: strategies for identification. *J Clin Psychiatry*. 2020;81. <https://doi.org/10.4088/JCPUT17042BR1C>.
- Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World health surveys. *Lancet*. 2007;370(9590):851–8. [https://doi.org/10.1016/S0140-6736\(07\)61415-9](https://doi.org/10.1016/S0140-6736(07)61415-9).
- Weinberger AH, Gbedemah M, Martinez AM, Nash D, Galea S, Goodwin RD. Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups. *Psychol Med*. 2018;48(8):1308–15. <https://doi.org/10.1017/S0033291717002781>.
- Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204–22. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9).
- Yang L, Zhao Y, Wang Y, Liu L, Zhang X, Li B, et al. The Effects of psychological stress on Depression. *Curr Neuropharmacol*. 2015;13(4):494–504. <https://doi.org/10.2174/1570159x1304150831150507>.
- Jeon B, Sereika SM, Callan JA, Luyster FS, DiNardo MM, Chasens ER. Age-Related differences in Mood, Diabetes-Related distress, and functional outcomes in adults with type 2 diabetes Mellitus and Comorbid Obstructive Sleep Apnea and Insomnia. *Diabetes Educ*. 2020;46(6):540–51. <https://doi.org/10.1177/0145721720958396>.
- Snoek FJ, Bremmer MA, Hermanns N. Constructs of depression and distress in diabetes: time for an appraisal. *Lancet Diabetes Endocrinol*. 2015;3(6):450–60. [https://doi.org/10.1016/S2213-8587\(15\)00135-7](https://doi.org/10.1016/S2213-8587(15)00135-7).
- Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*. 2001;24(6):1069–78. <https://doi.org/10.2337/diacare.24.6.1069>.
- Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of comorbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. *Diabet Med*. 2006;23(11):1165–73. <https://doi.org/10.1111/j.1464-5491.2006.01943.x>.
- Cao C, Hu L, Xu T, Liu Q, Koyanagi A, Yang L, et al. Prevalence, correlates and misperception of depression symptoms in the United States, NHANES 2015–2018. *J Affect Disord*. 2020;269:51–7. <https://doi.org/10.1016/j.jad.2020.03.031>.
- Wang Y, Lopez JM, Bolge SC, Zhu VJ, Stang PE. Depression among people with type 2 diabetes mellitus, US National Health and Nutrition Examination Survey (NHANES), 2005–2012. *BMC Psychiatry*. 2016;16:88. <https://doi.org/10.1186/s12888-016-0800-2>.
- Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, et al. Examining a bidirectional association between depressive symptoms and diabetes. *JAMA*. 2008;299(23):2751–9. <https://doi.org/10.1001/jama.299.23.2751>.
- Sartorius N. Depression and diabetes. *Dialogues Clin Neurosci*. 2018;20(1):47–52.
- Lloyd CE, Roy T, Nouwen A, Chauhan AM. Epidemiology of depression in diabetes: international and cross-cultural issues. *J Affect Disord*. 2012;142. [https://doi.org/10.1016/S0165-0327\(12\)70005-8](https://doi.org/10.1016/S0165-0327(12)70005-8). Suppl:S22–9.
- Semenkovich K, Brown ME, Svrakic DM, Lustman PJ. Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. *Drugs*. 2015;75(6):577–87. <https://doi.org/10.1007/s40265-015-0347-4>.

17. Wei J, Lu Y, Li K, Goodman M, Xu H. The associations of late-life depression with all-cause and cardiovascular mortality: the NHANES 2005–2014. *J Affect Disord*. 2022;300:189–94. <https://doi.org/10.1016/j.jad.2021.12.104>.
18. Inoue K, Mayeda ER, Nianogo R, Paul K, Yu Y, Haan M, et al. Estimating the joint effect of diabetes and subsequent depressive symptoms on mortality among older latinos. *Ann Epidemiol*. 2021;64:120–6. <https://doi.org/10.1016/j.annepidem.2021.09.007>.
19. Meng R, Yu C, Liu N, He M, Lv J, Guo Y, et al. Association of Depression with all-cause and Cardiovascular Disease Mortality among adults in China. *JAMA Netw Open*. 2020;3(2):e1921043. <https://doi.org/10.1001/jamanetworkopen.2019.21043>.
20. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. *Stress*. 2009;12(1):1–21. <https://doi.org/10.1080/10253890802046281>.
21. van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. *PLoS ONE*. 2013;8(3):e57058. <https://doi.org/10.1371/journal.pone.0057058>.
22. Salinero-Fort MA, Gomez-Campelo P, Cardenas-Valladolid J, San Andres-Rebollo FJ, de Miguel-Yanes JM, de Burgos-Lunar C, et al. Effect of depression on mortality in type 2 diabetes mellitus after 8 years of follow-up. The DIADEMA study. *Diabetes Res Clin Pract*. 2021;176:108863. <https://doi.org/10.1016/j.diabres.2021.108863>.
23. Prigge R, Wild SH, Jackson CA. Depression, diabetes, comorbid depression and diabetes and risk of all-cause and cause-specific mortality: a prospective cohort study. *Diabetologia*. 2022;65(9):1450–60. <https://doi.org/10.1007/s00125-022-05723-4>.
24. Jung I, Kwon H, Park SE, Han KD, Park YG, Kim YH, et al. Increased risk of Cardiovascular Disease and Mortality in patients with diabetes and coexisting Depression: a Nationwide Population-Based Cohort Study. *Diabetes Metab J*. 2021;45(3):379–89. <https://doi.org/10.4093/dmj.2020.0008>.
25. Guan S, Fang X, Gu X, Zhang Z, Tang Z, Wu X, et al. The link of depression, untreated hypertension, and diabetes with mortality in postmenopausal women: a cohort study. *Clin Exp Hypertens*. 2021;43(1):1–6. <https://doi.org/10.1080/10641963.2020.1790584>.
26. Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. *Diabetes Care*. 2003;26(10):2822–8. <https://doi.org/10.2337/diacare.26.10.2822>.
27. Reeves GC, Alhurani AS, Frazier SK, Watkins JF, Lennie TA, Moser DK. The association of comorbid diabetes mellitus and symptoms of depression with all-cause mortality and cardiac rehospitalization in patients with heart failure. *BMJ Open Diabetes Res Care*. 2015;3(1):e000077. <https://doi.org/10.1136/bmjdr-2014-000077>.
28. Kim YK, Na KS, Myint AM, Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016;64:277–84. <https://doi.org/10.1016/j.pnpb.2015.06.008>.
29. Moran LJ, Wilson CJ, Buckley JD, Noakes M, Clifton PM, Brinkworth GD. Changes in endothelial function and depression scores are associated following long-term dietary intervention: a secondary analysis. *Nutrition*. 2013;29(10):1271–4. <https://doi.org/10.1016/j.nut.2013.03.023>.
30. Owens-Gary MD, Zhang X, Jawanda S, Bullard KM, Allweiss P, Smith BD. The importance of addressing Depression and Diabetes distress in adults with type 2 diabetes. *J Gen Intern Med*. 2019;34(2):320–4. <https://doi.org/10.1007/s11606-018-4705-2>.
31. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. *Diabetes Care*. 2008;31(12):2398–403. <https://doi.org/10.2337/dc08-1341>.
32. Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: a meta-analysis and systematic review. *Gen Hosp Psychiatry*. 2013;35(3):217–25. <https://doi.org/10.1016/j.genhosppsych.2013.01.006>.
33. Saint-Maurice PF, Troiano RP, Bassett DR Jr, Graubard BI, Carlson SA, Shiroma EJ, et al. Association of Daily Step Count and Step Intensity with Mortality among US adults. *JAMA*. 2020;323(12):1151–60. <https://doi.org/10.1001/jama.2020.1382>.
34. Wang S, Wang Y, Wan X, Guo J, Zhang Y, Tian M, et al. Cobalamin Intake and related biomarkers: Examining Associations with mortality risk among adults with type 2 diabetes in NHANES. *Diabetes Care*. 2022;45(2):276–84. <https://doi.org/10.2337/dc21-1674>.
35. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol*. 2013;24(2):302–8. <https://doi.org/10.1681/ASN.2012070718>.
36. Levis B, Benedetti A, Ioannidis JPA, Sun Y, Negeri Z, He C, et al. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. *J Clin Epidemiol*. 2020;122:115–28. <https://doi.org/10.1016/j.jclinepi.2020.02.002>.
37. Levis B, Benedetti A, Thombs BD, Collaboration DESD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *BMJ*. 2019;365:11476. <https://doi.org/10.1136/bmj.11476>.
38. Chima CC, Salemi JL, Wang M, Mejia de Grubb MC, Gonzalez SJ, Zoorob RJ. Multimorbidity is associated with increased rates of depression in patients hospitalized with diabetes mellitus in the United States. *J Diabetes Complications*. 2017;31(11):1571–9. <https://doi.org/10.1016/j.jdiacomp.2017.08.001>.
39. Bojanic I, Sund ER, Sletvold H, Bjerkeset O. Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995–2019: the HUNT studies, Norway. *BMC Psychol*. 2021;9(1):130. <https://doi.org/10.1186/s40359-021-00636-0>.
40. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. *Can J Psychiatry*. 2006;51(2):100–13. <https://doi.org/10.1177/070674370605100206>.
41. Ferro MA, Gorter JW, Boyle MH. Trajectories of depressive symptoms during the transition to young adulthood: the role of chronic illness. *J Affect Disord*. 2015;174:594–601. <https://doi.org/10.1016/j.jad.2014.12.014>.
42. Demmer RT, Gelb S, Suglia SF, Keyes KM, Aiello AE, Colombo PC, et al. Sex differences in the association between depression, anxiety, and type 2 diabetes mellitus. *Psychosom Med*. 2015;77(4):467–77. <https://doi.org/10.1097/PSY.000000000000169>.
43. Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. *BMC Public Health*. 2014;14:1059. <https://doi.org/10.1186/1471-2458-14-1059>.
44. Alva ML. Co-occurrence of diabetes and depression in the U.S. *PLoS ONE*. 2020;15(6):e0234718. <https://doi.org/10.1371/journal.pone.0234718>.
45. Bjelland I, Krokstad S, Mykletun A, Dahl AA, Tell GS, Tambs K. Does a higher educational level protect against anxiety and depression? The HUNT study. *Soc Sci Med*. 2008;66(6):1334–45. <https://doi.org/10.1016/j.socscimed.2007.12.019>.
46. Buckman JEJ, Saunders R, Stott J, Arundell LL, O'Driscoll C, Davies MR, et al. Role of age, gender and marital status in prognosis for adults with depression: an individual patient data meta-analysis. *Epidemiol Psychiatr Sci*. 2021;30:e42. <https://doi.org/10.1017/S2045796021000342>.
47. Fluharty M, Taylor AE, Grabski M, Munafò MR. The association of cigarette smoking with depression and anxiety: a systematic review. *Nicotine Tob Res*. 2017;19(1):3–13. <https://doi.org/10.1093/ntr/ntw140>.
48. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. *Biol Psychiatry*. 2003;54(3):216–26. [https://doi.org/10.1016/s0006-3223\(03\)00273-7](https://doi.org/10.1016/s0006-3223(03)00273-7).
49. Noel PH, Williams JW Jr, Unutzer J, Worchel J, Lee S, Cornell J, et al. Depression and comorbid illness in elderly primary care patients: impact on multiple domains of health status and well-being. *Ann Fam Med*. 2004;2(6):555–62. <https://doi.org/10.1370/afm.143>.
50. Katon W, Schulberg H. Epidemiology of depression in primary care. *Gen Hosp Psychiatry*. 1992;14(4):237–. [https://doi.org/10.1016/0163-8343\(92\)90094-q](https://doi.org/10.1016/0163-8343(92)90094-q).
51. Harpole LH, Williams JW Jr, Olsen MK, Stechuchak KM, Oddone E, Callahan CM, et al. Improving depression outcomes in older adults with comorbid medical illness. *Gen Hosp Psychiatry*. 2005;27(1):4–12. <https://doi.org/10.1016/j.genhosppsych.2004.09.004>.
52. Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: current understanding. *J Clin Neurosci*. 2018;47:1–5. <https://doi.org/10.1016/j.jocn.2017.09.022>.
53. Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Willett WC, et al. Increased mortality risk in women with depression and diabetes mellitus. *Arch Gen Psychiatry*. 2011;68(1):42–50. <https://doi.org/10.1001/archgenpsychiatry.2010.176>.
54. Farooqi A, Khunti K, Abner S, Gillies C, Morriss R, Seidu S. Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: a systematic review and meta-analysis. *Diabetes Res Clin Pract*. 2019;156:107816. <https://doi.org/10.1016/j.diabres.2019.107816>.

55. Wu CS, Hsu LY, Wang SH. Association of depression and diabetes complications and mortality: a population-based cohort study. *Epidemiol Psychiatr Sci.* 2020;29:e96. <https://doi.org/10.1017/S2045796020000049>.
56. Kiely KM, Brady B, Byles J. Gender, mental health and ageing. *Maturitas.* 2019;129:76–84. <https://doi.org/10.1016/j.maturitas.2019.09.004>.
57. Affleck W, Carmichael V, Whitley R. Men's Mental Health: Social Determinants and Implications for Services. *Can J Psychiatry.* 2018;63(9):581–9. <https://doi.org/10.1177/0706743718762388>.
58. Gorman JM. Gender differences in depression and response to psychotropic medication. *Gend Med.* 2006;3(2):93–109. [https://doi.org/10.1016/s1550-8579\(06\)80199-3](https://doi.org/10.1016/s1550-8579(06)80199-3).
59. Schoevers RA, Geerlings MI, Beekman AT, Penninx BW, Deeg DJ, Jonker C, et al. Association of depression and gender with mortality in old age. Results from the Amsterdam Study of the Elderly (AMSTEL). *Br J Psychiatry.* 2000;177:336–42. <https://doi.org/10.1192/bjp.177.4.336>.
60. Yager S, Forlenza MJ, Miller GE. Depression and oxidative damage to lipids. *Psychoneuroendocrinology.* 2010;35(9):1356–62. <https://doi.org/10.1016/j.psyneuen.2010.03.010>.
61. Shah A, Bhat R, Zarate-Escudero S, DeLeo D, Erlangsen A. Suicide rates in five-year age-bands after the age of 60 years: the international landscape. *Aging Ment Health.* 2016;20(2):131–8. <https://doi.org/10.1080/13607863.2015.1055552>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.